Currently there is only one approved treatment for a specific and rare early onset retinal dystrophy called RPE65-associated retinal dystrophy, this has been approved by United States Food and Drug Administration (FDA) and European Medicines Agency (EMA). This evidence concerns the gene RPE65 and Retinal dystrophy.